Compare MLCI & INMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MLCI | INMB |
|---|---|---|
| Founded | N/A | 2015 |
| Country | United States | United States |
| Employees | 21 | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 31.3M | 37.2M |
| IPO Year | N/A | 2018 |
| Metric | MLCI | INMB |
|---|---|---|
| Price | $2.78 | $1.45 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $5.40 |
| AVG Volume (30 Days) | 26.0K | ★ 270.3K |
| Earning Date | 05-08-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.63% | N/A |
| EPS Growth | N/A | ★ 11.85 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $50,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 257.14 |
| 52 Week Low | $2.68 | $1.09 |
| 52 Week High | $8.68 | $11.64 |
| Indicator | MLCI | INMB |
|---|---|---|
| Relative Strength Index (RSI) | 33.45 | 58.27 |
| Support Level | $2.68 | $1.37 |
| Resistance Level | $3.13 | $1.52 |
| Average True Range (ATR) | 0.18 | 0.09 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 15.90 | 74.63 |
Mount Logan Capital Inc operates as emerging asset management and investment firm focused on investing in public and private debt securities in the North American market. The company's reporting segments include asset management and insurance. The company through its subsidiaries, earns management and incentive fees and servicing fees for providing investment management, monitoring and other services to investment vehicles and advisers. The Asset Management segment comprises all fee generating activities. The Insurance Solutions segment, which derives maximum revenue, consists of two product lines within the insurance business, LTC and MYGA.
INmune Bio Inc is a clinical stage biotechnology pharmaceutical company focused on developing and commercializing its product candidates to treat diseases where inflammation and immunology cause a dysfunctional immune system contributing to disease. The company's pipeline products include INKmune, XPro1595, and others. It has three product platforms; The CORDStrom product platform, The DN-TNF product platform, and The Natural Killer Cell Priming Platform.